Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady-State Pharmacokinetics of Vemurafenib in Patients With BRAF
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ administration & dosage
Cytochrome P-450 CYP3A Inhibitors
/ administration & dosage
Drug Interactions
Female
Humans
Itraconazole
/ administration & dosage
Male
Melanoma
/ blood
Middle Aged
Mutation
Protein Kinase Inhibitors
/ administration & dosage
Proto-Oncogene Proteins B-raf
/ genetics
Thyroid Neoplasms
/ blood
Vemurafenib
/ administration & dosage
Young Adult
CYP3A4
drug-drug interactions
itraconazole
pharmacokinetics
vemurafenib
Journal
Clinical pharmacology in drug development
ISSN: 2160-7648
Titre abrégé: Clin Pharmacol Drug Dev
Pays: United States
ID NLM: 101572899
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
23
12
2019
accepted:
11
05
2020
pubmed:
1
7
2020
medline:
16
12
2021
entrez:
1
7
2020
Statut:
ppublish
Résumé
The effects of itraconazole, a strong CYP3A4 inhibitor, on the steady-state pharmacokinetics of vemurafenib were evaluated in a phase 1, multicenter, open-label, fixed-sequence study. Patients with BRAF
Substances chimiques
Antineoplastic Agents
0
Cytochrome P-450 CYP3A Inhibitors
0
Protein Kinase Inhibitors
0
Vemurafenib
207SMY3FQT
Itraconazole
304NUG5GF4
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
39-45Informations de copyright
© 2020, The American College of Clinical Pharmacology.
Références
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAFv600E and BRAFv600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323-332.
Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-1876.
Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248-1260.
Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4(3):384-388.
Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714.
Grippo JF, Zhang W, Heinzmann D, et al. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma. Cancer Chemother Pharmacol. 2014;73(1):103-111.
Zhang W, Heinzmann D, Grippo JF. Clinical pharmacokinetics of vemurafenib. Clinical Pharmacokinet. 2017;56(9):1033-1043.
Ribas A, Zhang W, Chang I, et al. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol. 2014;54(4):368-374.
Zhang W, McIntyre C, Forbes H, et al. Effect of rifampicin on the pharmacokinetics of a single dose of vemurafenib in patients with BRAF(V600) mutation-positive metastatic malignancy. Clin Pharmacol Drug Dev. 2019;8(6):837-843.
Zhang W, McIntyre C, Kuhn M, et al. Effect of vemurafenib on the pharmacokinetics of a single dose of digoxin in patients with BRAF(V600) mutation-positive metastatic malignancy. J Clin Pharmacol. 2018;58(8):1067-1073.
Goldinger SM, Rinderknecht J, Dummer R, et al. A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Pharmacol Res Perspect. 2015;3(2):e00113.
Srinivas NR. Pharmacokinetic interaction of rifampicin with oral versus intravenous anticancer drugs: challenges, dilemmas and paradoxical effects due to multiple mechanisms. Drugs in R&D. 2016;16(2):141-148.
Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol. 1997;43:7-35.
Greenblatt DJ, Harmatz JS. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies. Br J Clin Pharmacol. 2015;80(3):342-350.